BACKGROUND: Although the protective effect of oral contraceptives (OCs) use against epithelial ovarian cancer is well-established, there remain gaps in our understanding of the contributions of time-related characteristics of OC use to risk. METHODS: This population-based case-control study, carried out in Hawaii and Los Angeles 1993-2006, included 813 cases of epithelial ovarian cancer and 992 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. RESULTS: Epithelial ovarian cancer risk was reduced 5 or more years after initiation of OC use (OR = 0.18; CI = 0.08-0.39). Each year of use provided a 5% reduction (CI = 2%-8%) in risk. A positive gradient in risk with time since first OC use was independent of duration of OC use. The inverse association of OCs with risk was attenuated decades after last use, but was not affected by age at first or last use. OC use for <1 year was associated with decreased ovarian cancer risk (OR = 0.45; CI = 0.26-0.79) only among recent users (< or =20 years from diagnosis/interview). Women who used OCs for a year or more were protected for at least 3 decades after they stopped use. CONCLUSIONS: Reduction in epithelial ovarian cancer risk associated with OC use became apparent after a short latency period and short duration of use, and was long-lasting. Time since first use and time since last use seem to modify the association of OCs with ovarian cancer risk independently of duration of use.
BACKGROUND: Although the protective effect of oral contraceptives (OCs) use against epithelial ovarian cancer is well-established, there remain gaps in our understanding of the contributions of time-related characteristics of OC use to risk. METHODS: This population-based case-control study, carried out in Hawaii and Los Angeles 1993-2006, included 813 cases of epithelial ovarian cancer and 992 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. RESULTS:Epithelial ovarian cancer risk was reduced 5 or more years after initiation of OC use (OR = 0.18; CI = 0.08-0.39). Each year of use provided a 5% reduction (CI = 2%-8%) in risk. A positive gradient in risk with time since first OC use was independent of duration of OC use. The inverse association of OCs with risk was attenuated decades after last use, but was not affected by age at first or last use. OC use for <1 year was associated with decreased ovarian cancer risk (OR = 0.45; CI = 0.26-0.79) only among recent users (< or =20 years from diagnosis/interview). Women who used OCs for a year or more were protected for at least 3 decades after they stopped use. CONCLUSIONS: Reduction in epithelial ovarian cancer risk associated with OC use became apparent after a short latency period and short duration of use, and was long-lasting. Time since first use and time since last use seem to modify the association of OCs with ovarian cancer risk independently of duration of use.
Authors: Lindsey Enewold; Louise A Brinton; Katherine A McGlynn; Shelia H Zahm; John F Potter; Kangmin Zhu Journal: J Womens Health (Larchmt) Date: 2010-05 Impact factor: 2.681
Authors: Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich Journal: Cancer Causes Control Date: 2017-03-14 Impact factor: 2.506
Authors: Amy L Shafrir; Helena Schock; Elizabeth M Poole; Kathryn L Terry; Rulla M Tamimi; Susan E Hankinson; Bernard A Rosner; Shelley S Tworoger Journal: Cancer Causes Control Date: 2017-03-13 Impact factor: 2.506
Authors: Merlise A Clyde; Rachel Palmieri Weber; Edwin S Iversen; Elizabeth M Poole; Jennifer A Doherty; Marc T Goodman; Roberta B Ness; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Nicolas Wentzensen; Alice S Whittemore; Hoda Anton-Culver; Elisa V Bandera; Andrew Berchuck; Michael E Carney; Daniel W Cramer; Julie M Cunningham; Kara L Cushing-Haugen; Robert P Edwards; Brooke L Fridley; Ellen L Goode; Galina Lurie; Valerie McGuire; Francesmary Modugno; Kirsten B Moysich; Sara H Olson; Celeste Leigh Pearce; Malcolm C Pike; Joseph H Rothstein; Thomas A Sellers; Weiva Sieh; Daniel Stram; Pamela J Thompson; Robert A Vierkant; Kristine G Wicklund; Anna H Wu; Argyrios Ziogas; Shelley S Tworoger; Joellen M Schildkraut Journal: Am J Epidemiol Date: 2016-10-03 Impact factor: 4.897
Authors: Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb Journal: Eur J Epidemiol Date: 2020-09-21 Impact factor: 8.082
Authors: Catherine M Olsen; Christina M Nagle; David C Whiteman; Roberta Ness; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Harvey A Risch; Herbert Yu; Jennifer A Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T Goodman; Michael E Carney; Rayna K Matsuno; Galina Lurie; Kirsten Moysich; Susanne K Kjaer; Allan Jensen; Estrid Hogdall; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Cathrine Hoyo; Patricia Moorman; Rachel P Weber; Daniel W Cramer; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Lorna Rodriguez-Rodriguez; Melony King; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Penelope M Webb Journal: Endocr Relat Cancer Date: 2013-03-22 Impact factor: 5.678
Authors: Iris L Romero; Ilyssa O Gordon; Sujatha Jagadeeswaran; Keeley L Mui; Woo Seok Lee; Daniela M Dinulescu; Thomas N Krausz; Helen H Kim; Melissa L Gilliam; Ernst Lengyel Journal: Cancer Prev Res (Phila) Date: 2009-09-08
Authors: R Calderon-Margalit; Y Friedlander; R Yanetz; K Kleinhaus; M C Perrin; O Manor; S Harlap; O Paltiel Journal: Am J Epidemiol Date: 2008-11-26 Impact factor: 4.897
Authors: Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore Journal: Int J Epidemiol Date: 2013-04 Impact factor: 7.196
Authors: Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry Journal: Cancer Causes Control Date: 2017-01-03 Impact factor: 2.506